Opinion|Videos|January 23, 2024
Approaches to Treatment and Staging in Unresectable NSCLC
Gregory Gan, MD, briefly outlines the available treatment strategies for stage III unresectable NSCLC, and Alykhan Nagji, MD explores the characterization of patients with unresectable stage III NSCLC, underscoring the crucial role of accurate staging in guiding treatment decisions.
Advertisement
Episodes in this series
Advertisement
Related to this article
David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.
Xiuning Le, MD, PhD, weighs sevabertinib against zongertinib and trastuzumab deruxtecan in HER2-mutant non–small cell lung cancer.
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.
Investigators are evaluating cesalatamig among patients with advanced cancer in the international phase 1/2 BiPAVE-001 trial.
The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
Based on updated data from the TRUST-1 trial, a sNDA for taletrectinib has been approved by the FDA for patients with TKI-naive ROS1+ NSCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer
3
Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera
4
AdenoVerse Platform Receives FDA Designation for HPV-Associated Cancers
5